Kenilworth Systems Corporation, originally focused on software technology, has shifted its focus to medical travel consulting through Regenecell and real estate investments via upcoming acquisitions, with minimal revenue and significant ownership concentration by Daniel Snyder.

# Summary of Kenilworth Systems Corporation

## Company Overview
- **Founded:** April 25, 1968 (originally in New York), reincorporated in Wyoming in 2023.
- **Trading Symbol:** “KENS” on OTC Pink Sheets.
- **Primary Business Focus:** Transitioned from software licensing and technology development to medical travel consulting and referral services through its subsidiary Regenecell, Inc.
- **Current Industry:** Medical travel consulting and referral services, specifically in the international medical tourism sector.

## Business Activities
- **Recent Acquisition:** On September 30, 2023, Kenilworth completed a share exchange to acquire a 60% controlling interest in Regenecell, Inc.
  - **Regenecell’s Business:** Provides medical travel consulting and referral services.
  - **Ownership Structure Post-Acquisition:** Kenilworth owns 600,000 shares (60%) of Regenecell; the founder Steven Swank owns 40%.
- **Expansion Plans:** The company aims to expand Regenecell’s international medical tourism operations and explore opportunities to modify its structure into a corporate holding company to acquire other technology companies.
- **Upcoming Business Transaction:** On February 6, 2025, Kenilworth entered into an agreement to acquire 100% of DC Rental Portfolio LLC’s membership interests for 350,000,000 shares of its stock.
  - **DC Rental’s Business:** Owns/in the process of acquiring income-producing residential housing units in Washington, D.C.
  - **Valuation Expectation at Closing:** Properties estimated to be worth at least $100 million, with approximately $20 million in equity.
  - **Name Change:** Will change its name to **National Real Estate Ventures, Inc.** upon closing.
  - **Leadership Change:** Richard Balles, the manager of DC Rental, will become President and Chairman, with a change in control of the company at that time.

## Financial Highlights
- **Employees:** No current employees; all administrative functions are provided by the two officers.
- **Revenue:** 
  - For the year ending December 31, 2024: **$5,000**.
  - For the year ending December 31, 2023: **$12,000**.
- **Net Income / Loss:**
  - 2024: **$(336,909)**
  - 2023: **$(166,151)**
- **Total Assets:** 
  - December 31, 2024: **$45,834**
  - December 31, 2023: **$68,184**
- **Liabilities:**
  - December 31, 2024: **$66,974**
  - December 31, 2023: **$74,914**
- **Stockholders’ Equity:**
  - December 31, 2024: **$(21,140)**
  - December 31, 2023: **$(6,731)**
- **Shares Outstanding:** 83,654,525 as of December 31, 2024.
- **Stock Ownership:**
  - Daniel W. Snyder holds approximately 57.4% of the common stock.
  - Other significant shareholders include Steven Swank (5.3%), Richard J. Cruse (3%), and Jay A. Cunningham, Sr. (1.8%).

## Business History
- Originally focused on developing patents, licensing, and software related to corporate licensing and online secure tools.
- Discontinued prior operations in 2023.
- Currently focused on expanding Regenecell and pursuing real estate investments via the upcoming acquisition.

## Summary
Kenilworth Systems Corporation has transitioned from technological and licensing ventures to focusing on medical travel consulting through Regenecell, and real estate investments via its planned acquisition of DC Rental. The 2024 revenue remains minimal, with a net loss reported for both 2023 and 2024. The company is in a period of strategic restructuring with significant acquisitions planned and no current employees but significant ownership concentration by Daniel Snyder.

Kenilworth Systems Corporation is a publicly traded company focusing on medical travel consulting services through its 60% ownership in Regenecell, Inc.

# Kenilworth Systems Corporation Overview

## Company Details
- **Incorporation Date**: April 25, 1968
- **Reincorporation**: State of Wyoming, 2023
- **Public Trading Status**: OTC Pink Sheet Market (trading symbol “KENS”)

## Current Business Operations
As of September 30, 2023, Kenilworth Systems Corporation has acquired a **60% equity interest in Regenecell, Inc.**, a Florida corporation engaged in **medical travel consulting and referral services**. 

### Key Information About Regenecell, Inc.:
- **Founder and President**: Steven Swank
- **Equity Ownership**:
  - Kenilworth: 600,000 Shares (60%)
  - Steven Swank: 400,000 Shares (40%)
- **Total Shares Authorized**: 1,000,000 Shares

### Business Focus
Kenilworth intends for Regenecell, Inc. to be its **sole line of business**, focusing on expanding operations in **international medical travel consulting and referral services**.

### Plans for Corporate Structure
Kenilworth is exploring the possibility of becoming a **Corporate Holding Company** to facilitate acquisitions of other emerging technology companies.

## Historical Business Operations
Previously, Kenilworth's operations focused on:
- **Omni-channel marketing**: Targeting advertising technology companies and brands.
- **Intellectual Property Development**: Engaging in patent development and governmental approvals.
  
### Asset Transactions
- **Acquisition of Intellectual Property**: On September 28, 2021, Kenilworth acquired assets from ACL Group, Inc.
- **Sale of Principal Assets**: On March 17, 2022, Kenilworth sold its principal assets back to ACL Group, Inc., cancelling a $300 million promissory note initially issued during an acquisition.

### License Agreement
- Entered into a **License Agreement with ACL** on March 28, 2022, with annual fees of **$500,000** and additional fees for implementation services.
- **Reversal of License Agreement**: The agreement was terminated on February 2, 2023, and the assets were returned to ACL in consideration of canceling the promissory note.

## Staffing
- **Employees**: Currently, Kenilworth has **no employees**. All business functions are managed by **two officers**.

## Financial Information
- **Revenue and Income**: Specific figures for revenues and income are not disclosed in the available information. Kenilworth has faced challenges related to cash flow and prior agreements.
  
## Customers
- **Customer Base**: Currently unspecified, focusing on medical travel consulting and referral services post-acquisition of Regenecell, Inc.

## Current Status Summary
- **Backlog**: None reported.
- **Legal Proceedings**: None reported.
- **Corporate Office**: Relocated to **Daytona Beach, FL** with office space provided by the President at no cost. 

## Executive Officers
- **Dan W. Snyder**: Chairman, President, CEO (Age: 72, Elected: 2022)
- **Steven Swank**: Director, Secretary, Chief Accounting Officer (Age: 83, Elected: 2023)
- **Richard J. Cruse**: Director (Age: 83, Elected: 2023)
- **Jay A. Cunningham, Sr.**: Director (Age: 85, Elected: 2023)

The Board plans to hold its next shareholders' meeting in the **2nd quarter of 2024**.

KENILWORTH SYSTEMS CORP

10-K / April 14, 2025

10-K / June 25, 2024

10-K / April 14, 2025

Summary of Kenilworth Systems Corporation

Company Overview

Business Activities

Financial Highlights

Business History

Summary